These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 14630347)

  • 1. Effects of orally administered levodopa on mesencephalic dopaminergic neurons undergoing a degenerative process.
    Ferrario JE; Delfino MA; Stefano AV; Zbarsky V; Douhou A; Murer MG; Raisman-Vozari R; Gershanik OS
    Neurosci Res; 2003 Dec; 47(4):431-6. PubMed ID: 14630347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions.
    Murer MG; Dziewczapolski G; Menalled LB; García MC; Agid Y; Gershanik O; Raisman-Vozari R
    Ann Neurol; 1998 May; 43(5):561-75. PubMed ID: 9585350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
    Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of L-3,4-dihydroxyphenylalanine and dopamine agonists on dopamine neurons in the progressive hemiparkinsonian rat models.
    Jeon MY; Lee WY; Kang HY; Chung EJ
    Neurol Res; 2007 Apr; 29(3):289-95. PubMed ID: 17509229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. β-asarone and levodopa coadministration increases striatal levels of dopamine and levodopa and improves behavioral competence in Parkinson's rat by enhancing dopa decarboxylase activity.
    Huang L; Deng M; Zhang S; Lu S; Gui X; Fang Y
    Biomed Pharmacother; 2017 Oct; 94():666-678. PubMed ID: 28787702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurotoxic effects of berberine on long-term L-DOPA administration in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Shin KS; Choi HS; Zhao TT; Suh KH; Kwon IH; Choi SO; Lee MK
    Arch Pharm Res; 2013 Jun; 36(6):759-67. PubMed ID: 23539311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
    Oiwa Y; Yoshimura R; Nakai K; Itakura T
    Brain Res; 2002 Aug; 947(2):271-83. PubMed ID: 12176170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KDI tripeptide of gamma1 laminin protects rat dopaminergic neurons from 6-OHDA induced toxicity.
    Väänänen AJ; Rauhala P; Tuominen RK; Liesi P
    J Neurosci Res; 2006 Aug; 84(3):655-65. PubMed ID: 16810683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of intrastriatal single injection of GDNF on the nigrostriatal dopaminergic system in hemiparkinsonian rats: behavioral and histological studies using two different dosages.
    Aoi M; Date I; Tomita S; Ohmoto T
    Neurosci Res; 2000 Apr; 36(4):319-25. PubMed ID: 10771110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions.
    Datla KP; Blunt SB; Dexter DT
    Mov Disord; 2001 May; 16(3):424-34. PubMed ID: 11391735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CART modulates the effects of levodopa in rat model of Parkinson's disease.
    Upadhya MA; Shelkar GP; Subhedar NK; Kokare DM
    Behav Brain Res; 2016 Mar; 301():262-72. PubMed ID: 26771081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CGP 3466 protects dopaminergic neurons in lesion models of Parkinson's disease.
    Waldmeier PC; Spooren WP; Hengerer B
    Naunyn Schmiedebergs Arch Pharmacol; 2000 Dec; 362(6):526-37. PubMed ID: 11138845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Degeneration of dopaminergic mesocortical neurons and activation of compensatory processes induced by a long-term paraquat administration in rats: implications for Parkinson's disease.
    Ossowska K; Smiałowska M; Kuter K; Wierońska J; Zieba B; Wardas J; Nowak P; Dabrowska J; Bortel A; Biedka I; Schulze G; Rommelspacher H
    Neuroscience; 2006 Sep; 141(4):2155-65. PubMed ID: 16797138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitamin D(3) attenuates 6-hydroxydopamine-induced neurotoxicity in rats.
    Wang JY; Wu JN; Cherng TL; Hoffer BJ; Chen HH; Borlongan CV; Wang Y
    Brain Res; 2001 Jun; 904(1):67-75. PubMed ID: 11516412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
    Fleming SM; Delville Y; Schallert T
    Behav Brain Res; 2005 Jan; 156(2):201-13. PubMed ID: 15582106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levodopa induces long-lasting modification in the functional activity of the nigrostriatal pathway.
    Riverol M; Ordóñez C; Collantes M; DiCaudo C; Peñuelas I; Arbizu J; Marcilla I; Luquin MR
    Neurobiol Dis; 2014 Feb; 62():250-9. PubMed ID: 24076099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Susceptibility of ascending dopamine projections to 6-hydroxydopamine in rats: effect of hypothermia.
    Grant RJ; Clarke PB
    Neuroscience; 2002; 115(4):1281-94. PubMed ID: 12453497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adaptive down-regulation of the serotonin transporter in the 6-hydroxydopamine-induced rat model of preclinical stages of Parkinson's disease and after chronic pramipexole treatment.
    Berghauzen-Maciejewska K; Wardas J; Kosmowska B; Domin H; Śmiałowska M; Głowacka U; Ossowska K
    Neuroscience; 2016 Feb; 314():22-34. PubMed ID: 26628402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning.
    Guigoni C; Dovero S; Aubert I; Li Q; Bioulac BH; Bloch B; Gurevich EV; Gross CE; Bezard E
    Eur J Neurosci; 2005 Jul; 22(1):283-7. PubMed ID: 16029219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic, systemic treatment with a metabotropic glutamate receptor 5 antagonist in 6-hydroxydopamine partially lesioned rats reverses abnormal firing of dopaminergic neurons.
    Chen L; Zhang QJ; Liu J; Wang S; Ali U; Gui ZH; Wang Y
    Brain Res; 2009 Aug; 1286():192-200. PubMed ID: 19545547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.